Hepatic chemerin mRNA in morbidly obese patients with nonalcoholic fatty liver disease
| Autor: | Rafał J. Bułdak, Maciej Kajor, Tomasz Sawczyn, Dominika Żądło, Marek Hartleb, Marek Waluga, Michał Kukla, Michał Dyaczyński, Anna Kostrząb-Zdebel, Łukasz Liszka, Mateusz Chapuła, Grzegorz Kowalski, Agnieszka Berdowska |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
nonalcoholic fatty liver disease
Adult 0301 basic medicine medicine.medical_specialty lcsh:Medicine Adipokine Adipose tissue CMKLR1 Pathology and Forensic Medicine 03 medical and health sciences Ballooning degeneration Non-alcoholic Fatty Liver Disease Fibrosis Internal medicine Nonalcoholic fatty liver disease medicine Humans Chemerin RNA Messenger adipokine biology business.industry lcsh:R General Medicine medicine.disease Obesity Morbid 030104 developmental biology Endocrinology Liver biology.protein Intercellular Signaling Peptides and Proteins Female Chemokines Steatosis business chemerin chemokine receptor-like 1 |
| Zdroj: | Polish Journal of Pathology, Vol 68, Iss 2, Pp 117-127 (2017) |
| ISSN: | 1233-9687 |
| DOI: | 10.5114/pjp.2017.69687 |
| Popis: | The aim of this study was to investigate hepatic chemerin mRNA, serum chemerin concentration, and immunohistochemical staining for chemerin and and chemokine receptor-like 1 (CMKLR1) in hepatic tissue in 56 morbidly obese women with nonalcoholic fatty liver disease (NAFLD) and to search for a relationship with metabolic and histopathological features. Chemerin mRNA was assessed by quantitative real-time PCR, chemerin, and CMKLR1 immunohistochemical expression with specific antibodies, while serum chemerin concentration was assessed with commercially available enzyme-linked immunosorbent assays. Serum chemerin concentration reached 874.1 ±234.6 ng/ml. There was no difference in serum chemerin levels between patients with BMI < 40 kg/m2 and ≥ 40 kg/m2. Serum chemerin concentration tended to be higher in patients with hepatocyte ballooning, greater extent of steatosis, and definite nonalcoholic steatohepatitis (NASH). Liver chemerin mRNA was observed in all included patients and was markedly, but insignificantly, higher in those with BMI ≥ 40 kg/m2, hepatocyte ballooning, greater extent of steatosis, and definite NASH. Hepatic chemerin mRNA might be a predictor of hepatic steatosis, hepatocyte ballooning, and NAFLD activity score (NAS) but seemed not to be a primary driver regulating liver necroinflammatory activity and fibrosis. The lack of association between serum chemerin and hepatic chemerin mRNA may suggest that adipose tissue but not the liver is the main source of chemerin in morbidly obese women. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|